Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Specimen Handling 602pembrolizumab 557Magnetic Resonance Spectroscopy 527Carboplatin 422Cyclophosphamide 370Cisplatin 369Biopsy 349Paclitaxel 304Gemcitabine 299Nivolumab 298Radiotherapy 256Bevacizumab 232Dexamethasone 207fludarabine 203Docetaxel 185durvalumab 177atezolizumab 172Oxaliplatin 170Fluorouracil 166venetoclax 164Rituximab 163Pemetrexed 161Doxorubicin 157Radiation 155Capecitabine 155Radiosurgery 145Etoposide 137Leucovorin 133Ipilimumab 132Lenalidomide 129

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × voruciclib × 90 days × Clear all
NCT03547115 2026-03-17

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

MEI Pharma, Inc.

Phase 1 Terminated
84 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡